Research programme: nuclear importation inhibitors - Presidio Pharmaceuticals

Drug Profile

Research programme: nuclear importation inhibitors - Presidio Pharmaceuticals

Alternative Names: CNI-H0294; H0294; ITI-001; PPI-367

Latest Information Update: 01 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytokine PharmaSciences; Presidio Pharmaceuticals
  • Class Pyrimidines; Small molecules
  • Mechanism of Action Nuclear importation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HIV infections; HIV-1 infections

Most Recent Events

  • 12 Jan 2007 Preclinical compounds and NEXT™ technology licensed to Presidio Pharmaceuticals worldwide
  • 29 Sep 2006 This programme is still in active development
  • 12 Aug 2002 Preclinical trials in HIV infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top